Seven Corners has published a writeup regarding Allergan's 2nd quarter and 1st half 2017 financial results, regarding which we note the following:
Allergan’s non-GAAP financial metrics continue to mislead.
In the writeup we review Allergan’s Q2 and 1H 2017 financial results.
GAAP results highlight clearly declining operational performance.
We reiterate our $117 target share price for Allergan.
To find a PDF containing our full AGN writeup, please visit our Research section (link here).